Essential Functional Molecules Associated with SARS-CoV-2 Infection: Potential Therapeutic Targets for COVID-19

Overview

Journal Gene

Specialty Molecular Biology

Date 2020 Nov 21

PMID 33220345

Citations 20

Authors

Keshav Rajarshi

Rajni Khan

Mrityunjay K Singh

Tushar Ranjan

Sandipan Ray

Shashikant Ray

Affiliations

Soon will be listed here.

Abstract

The whole world is still suffering substantially from the coronavirus disease 2019 (COVID-19) outbreak. Several protein-based molecules that are associated with the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which are essential for its functionality, survival, and pathogenesis have been identified and are considered as potential therapeutic targets. These protein-based molecules are either structural/non-structural components of SARS-CoV-2 or host factors, which play a crucial role in this infection. Developing drug molecules against these essential functional molecules to hinder their regular functioning and associated physiological pathways could be promising for successful clinical management of this novel coronavirus infection. The review aims to highlight the functional molecules that play crucial roles in SARS-CoV-2 pathogenesis. We have emphasized how these potential druggable targets could be beneficial in tackling the COVID-19 crisis.

Citing Articles

The role of epithelial-mesenchymal transition in pulmonary fibrosis: lessons from idiopathic pulmonary fibrosis and COVID-19.

Niayesh-Mehr R, Kalantar M, Bontempi G, Montaldo C, Ebrahimi S, Allameh A Cell Commun Signal. 2024; 22(1):542.

PMID: 39538298 PMC: 11558984. DOI: 10.1186/s12964-024-01925-y.

Host factors of SARS-CoV-2 in infection, pathogenesis, and long-term effects.

Zhang Y, Chen S, Tian Y, Fu X Front Cell Infect Microbiol. 2024; 14:1407261.

PMID: 38846354 PMC: 11155306. DOI: 10.3389/fcimb.2024.1407261.

Alterations in Circadian Rhythms, Sleep, and Physical Activity in COVID-19: Mechanisms, Interventions, and Lessons for the Future.

Das S, Khan R, Banerjee S, Ray S, Ray S Mol Neurobiol. 2024; 61(12):10115-10137.

PMID: 38702566 DOI: 10.1007/s12035-024-04178-5.

Computational Characterization of the Binding Properties of the HIV1-Neutralizing Antibody PG16 and Design of PG16-Derived CDRH3 Peptides.

Deubler M, Weissenborn L, Leukel S, Horn A, Eichler J, Sticht H Biology (Basel). 2023; 12(6).

PMID: 37372110 PMC: 10295463. DOI: 10.3390/biology12060824.

Impairment of antiviral immune response and disruption of cellular functions by SARS-CoV-2 ORF7a and ORF7b.

Garcia-Garcia T, Fernandez-Rodriguez R, Redondo N, de Lucas-Rius A, Zaldivar-Lopez S, Lopez-Ayllon B iScience. 2022; 25(11):105444.

PMID: 36310646 PMC: 9597514. DOI: 10.1016/j.isci.2022.105444.

References

Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S . Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020; 30(4):343-355. PMC: 7104723. DOI: 10.1038/s41422-020-0305-x. View

Chu C, Gadthula S, Chen X, Choo H, Olgen S, Barnard D . Antiviral activity of nucleoside analogues against SARS-coronavirus (SARS-coV). Antivir Chem Chemother. 2006; 17(5):285-9. DOI: 10.1177/095632020601700506. View

Schoeman D, Fielding B . Coronavirus envelope protein: current knowledge. Virol J. 2019; 16(1):69. PMC: 6537279. DOI: 10.1186/s12985-019-1182-0. View

Ge X, Li J, Yang X, Chmura A, Zhu G, Epstein J . Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013; 503(7477):535-8. PMC: 5389864. DOI: 10.1038/nature12711. View

Subissi L, Imbert I, Ferron F, Collet A, Coutard B, Decroly E . SARS-CoV ORF1b-encoded nonstructural proteins 12-16: replicative enzymes as antiviral targets. Antiviral Res. 2013; 101:122-30. PMC: 7113864. DOI: 10.1016/j.antiviral.2013.11.006. View

Munster V, Koopmans M, van Doremalen N, van Riel D, de Wit E . A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment. N Engl J Med. 2020; 382(8):692-694. DOI: 10.1056/NEJMp2000929. View

Fang L, Karakiulakis G, Roth M . Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med. 2020; 8(4):e21. PMC: 7118626. DOI: 10.1016/S2213-2600(20)30116-8. View

Gordon D, Jang G, Bouhaddou M, Xu J, Obernier K, White K . A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020; 583(7816):459-468. PMC: 7431030. DOI: 10.1038/s41586-020-2286-9. View

Sola I, Almazan F, Zuniga S, Enjuanes L . Continuous and Discontinuous RNA Synthesis in Coronaviruses. Annu Rev Virol. 2016; 2(1):265-88. PMC: 6025776. DOI: 10.1146/annurev-virology-100114-055218. View

10.

Backer J, Klinkenberg D, Wallinga J . Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill. 2020; 25(5). PMC: 7014672. DOI: 10.2807/1560-7917.ES.2020.25.5.2000062. View

11.

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

12.

Taylor J, Coleman C, Postel S, Sisk J, Bernbaum J, Venkataraman T . Severe Acute Respiratory Syndrome Coronavirus ORF7a Inhibits Bone Marrow Stromal Antigen 2 Virion Tethering through a Novel Mechanism of Glycosylation Interference. J Virol. 2015; 89(23):11820-33. PMC: 4645327. DOI: 10.1128/JVI.02274-15. View

13.

Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y . Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020; 10(5):766-788. PMC: 7102550. DOI: 10.1016/j.apsb.2020.02.008. View

14.

Shum K, Tanner J . Differential inhibitory activities and stabilisation of DNA aptamers against the SARS coronavirus helicase. Chembiochem. 2008; 9(18):3037-45. PMC: 7161993. DOI: 10.1002/cbic.200800491. View

15.

de Groot R, Baker S, Baric R, Brown C, Drosten C, Enjuanes L . Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013; 87(14):7790-2. PMC: 3700179. DOI: 10.1128/JVI.01244-13. View

16.

Li S, Wang C, Jou Y, Huang S, Hsiao L, Wan L . SARS Coronavirus Papain-Like Protease Inhibits the TLR7 Signaling Pathway through Removing Lys63-Linked Polyubiquitination of TRAF3 and TRAF6. Int J Mol Sci. 2016; 17(5). PMC: 4881504. DOI: 10.3390/ijms17050678. View

17.

Te Velthuis A, van den Worm S, Snijder E . The SARS-coronavirus nsp7+nsp8 complex is a unique multimeric RNA polymerase capable of both de novo initiation and primer extension. Nucleic Acids Res. 2011; 40(4):1737-47. PMC: 3287201. DOI: 10.1093/nar/gkr893. View

18.

Barcena M, Oostergetel G, Bartelink W, Faas F, Verkleij A, Rottier P . Cryo-electron tomography of mouse hepatitis virus: Insights into the structure of the coronavirion. Proc Natl Acad Sci U S A. 2009; 106(2):582-7. PMC: 2613939. DOI: 10.1073/pnas.0805270106. View

19.

Chan J, Kok K, Zhu Z, Chu H, To K, Yuan S . Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020; 9(1):221-236. PMC: 7067204. DOI: 10.1080/22221751.2020.1719902. View

20.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View